Evaluation of the effect of Gabapentin in patients with myocardial infarctio

Phase 2

Recruiting

• Conditions: Myocardial infarction with non-ST elevation.; Non-ST elevation (NSTEMI) myocardial infarction; I21.4

• Registration Number: IRCT20220516054874N2
• Lead Sponsor: Mashhad University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 29 August 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 68

Inclusion Criteria

Patients with non-ST-elevation MI according to the American College of Heart criteria
Consent to admission to the study
Age more than 18 years old
No use of alprazolam and opioids in the admission
No kidney failure under hemodialysis
No kidney failure and GFR<30
No thrombocytopenia
No severe liver failure with liver enzymes three times more than normal
No treatment with corticosteroids or immunosuppressive drugs
No treatment with diltiazem or verapamil
No history or prone to suicide
No previous treatment with gabapentin
Not engaging in sensitive jobs such as driving, piloting, police

Exclusion Criteria

Lack of consent to continue the study

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Changes in hs-CRP serum level. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Laboratory kit.

Secondary Outcome Measures

Name	Time	Method
Changes in CBC diff. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Laboratory kit.;Changes in lipid profile. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Laboratory kit.